These data were further consolidated by seven recently published studies, which corroborated the valuable role of KIF2C as a biomarker correlated with poor prognosis for all breast cancer subtypes [130,131,134–138] (Figure 3(A), OS; mean HR 1.79 [1.49–2.20]). This evidence concerns the gene KIF2C and breast carcinoma.